Login to Your Account

Iressa Results Stir Reactions Among Competitors, Investors

By Brady Huggett

Wednesday, August 21, 2002
AstraZeneca plc had the distinct but risky opportunity of providing those watching biotechnology with the first glimpse of data from a Phase III trial of an endothelial growth factor receptor inhibitor in combination with other cancer treatments. That honor proffered unfavorable results that Monday helped drag down a sizable chunk of the sector's stocks. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription